Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOSS: Biojector 2000 Safety Study for Fuzeon
NCT00337701Phase 4Completed
- Sponsor
- Roche
- Start
- Jun 2006
- Primary completion
- Jan 2007
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of enfuvirtide in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Roche. Primary endpoint: Composite endpoint (pain, induration, nodules/cysts). Started Jun 2006; status: completed.
02
Drugs
enfuvirtide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00337701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00337701.